Source:
@ARTICLE{Pomeroy2002,
author = {Scott L
Pomeroy and Pablo Tamayo and Michelle Gaasenbeek and
Lisa M Sturla and Michael Angelo and Margaret E
McLaughlin and John Y H Kim and Liliana C Goumnerova and Peter M Black and Ching
Lau and Jeffrey C Allen and David Zagzag and James M
Olson and Tom Curran and Cynthia Wetmore and Jaclyn A Biegel
and Tomaso Poggio and Shayan Mukherjee and Ryan Rifkin
and Andrea Califano and Gustavo Stolovitzky
and David N Louis and Jill P Mesirov and Eric S
Lander and Todd R Golub},
title = {Prediction of central nervous system embryonal tumour outcome based on
gene expression.},
journal = {Nature},
year = {2002},
volume = {415},
pages = {436--442},
number = {6870},
month = {Jan},
doi = {10.1038/415436a},
url = {http://dx.doi.org/10.1038/415436a}
}
Original data: http://www.broad.mit.edu/mpr/CNS/
Description:
Embryonal tumours of the central nervous system (CNS)
represent a heterogeneous group of tumours about
which little is known biologically, and whose diagnosis, on the basis of
morphologic appearance alone, is controversial. medulloblastomas
(MD), for example, are the most common
malignant brain tumour of childhood, but their
pathogenesis is unknown, their relationship to other embryonal
CNS tumours is debated, and patients' response to therapy
is difficult to predict. The authors approached these problems by developing a
classification system based on DNA microarray gene expression data derived from
99 patient samples. They demonstrate that medulloblastomas
are molecularly distinct from other brain tumours
including primitive neuroectodermal tumours (PNETs), atypical teratoid/rhabdoid tumours (Rhab) and malignant gliomas (Mglio). Within the class of medulloblastomas
(MD), they also studied the heterogeneity of classic (C) desmoplastic
(D) ones. In the analysis, normal
tissues were also considered (Ncer).
Parameters used in our filter: